OLI recorded this information on 9/11/2014
Abbott's board has authorized the repurchase of up to $3 billion of the corporation's common shares. This new authorization is in addition to the $511 million unused portion of the previous program that was announced in June 2013. The purchases may be made from time to time as market conditions warrant and subject to regulatory considerations.
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a range of health care products. Co.'s reportable segments are: established pharmaceutical products, which includes a range of generic pharmaceuticals; diagnostic products, which includes a range of diagnostic systems and tests; nutritional products, which includes a range of pediatric and adult nutritional products; and medical devices, which includes a range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices.
Abbott Laboratories SEC Filing Email Alerts Service
Open the ABT Page at The Online Investor »
Strong Buy (3.53 out of 4)